Anti-Müllerian Hormone (AMH) Dynamics: Evaluating Ovarian Reserve in Primary Infertility

Primary infertility is defined as the inability to achieve pregnancy after at least 12 months of regular, unprotected sexual intercourse in couples with no previous history of conception. Female fertility depends on multiple factors, including ovulatory function, tubal patency, uterine health, and ovarian reserve. Among the various biomarkers used to assess reproductive potential, Anti-Müllerian Hormone (AMH) has emerged as one of the most valuable tools for evaluating ovarian reserve.

AMH provides important information about the quantity of remaining ovarian follicles and assists clinicians in fertility assessment, treatment planning, and predicting ovarian response during assisted reproductive technologies.

This article explores the physiology, clinical significance, interpretation, and limitations of Anti-Müllerian Hormone (AMH) dynamics in the evaluation of ovarian reserve among women with primary infertility.

Understanding Ovarian Reserve

Ovarian reserve refers to the number and quality of follicles remaining within the ovaries.

Women are born with a finite number of primordial follicles. This pool progressively declines with age through a natural process known as follicular atresia.

As ovarian reserve diminishes:

• Fertility potential decreases.
• Oocyte quality declines.
• Response to fertility treatments may be reduced.

Assessment of ovarian reserve is therefore an essential component of infertility evaluation.

What Is Anti-Müllerian Hormone (AMH)?

Anti-Müllerian Hormone is a glycoprotein hormone produced primarily by granulosa cells of small growing ovarian follicles.

AMH secretion occurs predominantly in:

• Pre-antral follicles
• Small antral follicles

Because AMH production reflects the number of developing follicles, serum AMH concentrations serve as an indirect marker of ovarian reserve.

Unlike several reproductive hormones, AMH levels remain relatively stable throughout the menstrual cycle, making testing convenient.

Physiology of AMH Production

Follicular development begins with recruitment of dormant primordial follicles.

As follicles mature:

1. Primordial follicles become primary follicles.
2. Primary follicles develop into pre-antral follicles.
3. Granulosa cells begin producing AMH.
4. AMH production peaks in small antral follicles.
5. Larger dominant follicles produce minimal AMH.

AMH plays an important physiological role by:

• Regulating follicular recruitment.
• Preventing excessive follicular activation.
• Modulating ovarian responsiveness to follicle-stimulating hormone (FSH).

AMH Dynamics Across the Reproductive Lifespan

AMH concentrations vary significantly with age.

Childhood and Puberty

AMH levels rise gradually during childhood and adolescence as ovarian activity increases.

Reproductive Years

AMH concentrations generally peak during early adulthood and gradually decline thereafter.

Advanced Reproductive Age

As the ovarian follicle pool diminishes, AMH levels progressively decrease.

Very low or undetectable AMH levels may indicate diminished ovarian reserve or impending menopause.

Clinical Role of AMH in Primary Infertility

AMH testing has become an integral part of infertility investigations.

Important clinical applications include:

Assessment of Ovarian Reserve

AMH provides an estimate of the remaining follicular pool.

Low AMH levels may suggest:

• Diminished ovarian reserve
• Reduced reproductive potential

Prediction of Ovarian Response

AMH is widely used to predict ovarian response during assisted reproductive treatments.

Women with:

• Low AMH may demonstrate poor ovarian response.
• High AMH may exhibit excessive ovarian response.

Fertility Treatment Planning

AMH helps clinicians individualize treatment protocols.

Examples include:

• Selection of ovarian stimulation regimens
• Gonadotropin dose adjustments
• Counseling regarding prognosis

AMH Testing Procedure

AMH measurement is performed using a blood test.

Advantages include:

• Testing can be performed on almost any day of the menstrual cycle.
• Fasting is generally not required.
• Results are minimally affected by short-term hormonal fluctuations.

Laboratory methods continue to evolve, improving assay accuracy and standardization.

Interpretation of AMH Levels

AMH values should always be interpreted within the broader clinical context. General interpretations include:

• Very Low AMH: May indicate significantly diminished ovarian reserve and reduced ovarian response during fertility treatment.

• Low AMH: Suggests reduced ovarian reserve, which may affect fertility potential and response to ovarian stimulation.

• Normal AMH: Typically indicates an adequate ovarian reserve and expected ovarian responsiveness for the individual's age.

• High AMH: May reflect increased ovarian reserve and is commonly observed in women with Polycystic Ovary Syndrome (PCOS), where multiple small follicles produce excess AMH.

It is important to note that AMH reference ranges can vary between laboratories, and results should always be interpreted by a healthcare professional in conjunction with age, clinical history, and other fertility assessments.

It is important to recognize that AMH reflects follicle quantity rather than oocyte quality.

AMH and Age: An Important Relationship

Age remains the single most important determinant of female fertility.

Two women with similar AMH levels may have different reproductive outcomes depending on age.

For example:

• Younger women with low AMH may still achieve pregnancy.
• Older women with normal AMH may experience reduced fertility due to age-related decline in oocyte quality.

Therefore, AMH should never be interpreted in isolation.

AMH and Polycystic Ovary Syndrome (PCOS)

Women with Polycystic Ovary Syndrome frequently exhibit elevated AMH concentrations.

In PCOS:

• Numerous small follicles produce increased AMH.
• Follicular maturation may be impaired.
• Ovulatory dysfunction commonly occurs.

High AMH levels in women with PCOS may predict an exaggerated response during ovarian stimulation.

Careful treatment planning is therefore essential.

AMH in Assisted Reproductive Technologies

AMH has transformed the practice of reproductive medicine.

In Vitro Fertilization (IVF)

During IVF, AMH assists clinicians in:

• Predicting oocyte yield
• Selecting stimulation protocols
• Preventing ovarian hyperstimulation syndrome (OHSS)

Oocyte Cryopreservation

AMH assessment may help counsel women considering fertility preservation.

Donor Selection and Counseling

AMH contributes to prognostic counseling regarding expected treatment outcomes.

Limitations of AMH Testing

Despite its clinical utility, AMH testing has limitations.

AMH Does Not Predict Natural Fertility Precisely

A woman with low AMH may still conceive naturally.

Similarly, normal AMH does not guarantee pregnancy.

AMH Does Not Measure Egg Quality

AMH estimates follicle quantity rather than chromosomal competence or embryo quality.

Laboratory Variability

Differences among assay techniques may influence reported values.

Multiple Factors Influence Fertility

Successful conception also depends on:

• Tubal patency
• Sperm quality
• Uterine health
• Ovulatory function

Comprehensive fertility evaluation remains essential.

Additional Tests Used Alongside AMH

AMH is commonly combined with other investigations.

These may include:

Antral Follicle Count (AFC)

Transvaginal ultrasound evaluates visible follicles within the ovaries.

Follicle-Stimulating Hormone (FSH)

Elevated FSH may indicate declining ovarian reserve.

Estradiol Levels

Estradiol assessment may provide additional information regarding ovarian function.

Pelvic Ultrasound

Ultrasound evaluates ovarian morphology and uterine anatomy.

Counseling Patients About AMH Results

Patients should receive individualized counseling regarding AMH findings.

Healthcare providers should explain:

• The meaning of AMH levels
• Age-related fertility considerations
• Treatment options
• Prognostic expectations

Appropriate counseling reduces anxiety and facilitates informed decision-making.

Conclusion

Anti-Müllerian Hormone (AMH) has become an indispensable biomarker for evaluating ovarian reserve in women with primary infertility. By reflecting the remaining follicular pool, AMH assists clinicians in fertility assessment, individualized treatment planning, and prediction of ovarian response during assisted reproductive therapies.

Although AMH provides valuable information, it should always be interpreted alongside age, clinical history, ultrasound findings, and other fertility investigations. A comprehensive, patient-centered approach remains essential for optimizing reproductive outcomes and guiding evidence-based fertility care.